EFFECT OF DENOSUMAB ON BONE MINERAL DENSITY AND MARKERS OF BONE TURNOVER AMONG POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

SANCHEZ A; BRUN L; COSTANZO PR; GONZALEZ D; BAGUR A; OLIVERI B; ZANCHETTA MB; FARIAS V; MAFFEI L; PEMROU V; MANZUR JL; LARROUDÉ MARÍA SILVIA; SARLI MA; REY P; ULLA MR; PAVLOVE MM; KARLSBRUM S; BRANCE ML

Journal of Osteoporosis

Hindawi Publishing

Lugar: El Cairo; Año: 2016

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density(BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab inbisphosphonate-naïve patients (BP-naïve) compared to patients previously treated withbisphosphonates (BP-prior) was analyzed. This retrospective study included 425postmenopausal women treated with Dmab for 1 year in clinical practice conditions inspecialized centers from Argentina. Participants were also divided according to previousbisphosphonate treatment in BP-naïve and BP-prior. A control group of patients treated with BPnot switched to Dmab matched by sex, age and body mass index was used. Data areexpressed as mean±SEM. After 1 year of treatment with Dmab the bone formation markers totalalkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%,respectively), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMDwere observed at the lumbar spine, femoral neck and total hip without differences between BPnaïve and BP-prior. A better BMD response was found in BP-prior group compared with BPtreated patients not switched to Dmab. Conclusion: Dmab treatment increased BMD anddecreased bone turnover markers in the whole group, with similar response in BP-naïve andBP-prior patients. A better BMD response in BP-prior patients versus BP treated patients notswitched to Dmab was observed.